Gain Therapeutics shares surge 31.10% intraday on presentation of Parkinson's Phase 1b data at Oppenheimer Conference.

Gain Therapeutics surged 31.10% intraday following its scheduled presentation at the Oppenheimer Healthcare Conference, where the company highlighted updates on its Parkinson's disease candidate GT-02287. The market reacted positively to the anticipation of key Phase 1b biomarker data, which could support the drug's potential as a disease-modifying therapy. This event aligns with the stock’s historical volatility around clinical milestones, as seen after its December 18 Phase 1b data release. The presentation underscored strategic progress in its pipeline, fueling investor optimism ahead of the March 26 earnings report and reinforcing near-term catalysts for the stock.